Extending hepatitis C treatment for liver transplant patients may be beneficial
1 Nov 2009, 1202 Hrs

Add comment          Mail          Print          Write to Editor

Washington, Nov 1 A study by doctors at Henry Ford Hospital has shown that extending hepatitis C treatment for liver transplant patients results in high rates of clearance of the hepatitis C virus from the blood, as well as a low rate of relapse.

"We found that patients who achieved a sustained virological response were more likely to have had extended treatment. In addition, prolonging treatment for 52 weeks after patients were virus negative, resulted in a relapse rate of only 8 percent," said Kimberly Brown, Division head of Gastroenterology at Henry Ford Hospital and senior author of the study.

This is in contrast to typical relapse rates of 30-35 percent in non-transplant patients treated with standard therapy.

The study looked at 241 consecutive liver transplant patients from 1999-2006. Patients were offered treatment if they tested positive hepatitis C, had recurrent hepatitis C with at least Stage I fibrosis on biopsy, and stable immunosuppression for a minimum of three months.

Patients received either non-pegylated interferon tiw or pegylated interferon weekly in combination with ribavirin.

Of the study patients with hepatitis C, 66 were eligible for treatment, and 22 achieved sustained virological response. Only two patients (8 percent) relapsed.

After week 24 of treatment, 35 percent of patients who achieved a sustained virologic response became virus negative.

"These results call into question previous studies which suggested 'stop rules' at weeks 12 and 24 when there is no response to inferferon and ribravirin," Dr. Brown said.

"Our results suggest that even if patients are positive at week 24, there is still a 35 percent chance that they can achieve sustained viral clearance. We think this may be beneficial to extend treatment beyond the standard 48 weeks total," Dr. Brown added.

The results of the study will be presented during an oral presentation Oct. 31 at the American Association for the Study of iver Diseases' Annual Meeting in Boston. (ANI)

Related Latest

'Unimpressed' PCB may sack ageing Alam after Kiwi tour Surgery may reverse type 2 diabetes in morbidly obese people Global warming may be unstoppable, says scientist Surgery may reverse type 2 diabetes in morbidly obese people Global warming may be unstoppable, says scientist Global warming may increase chances of civil war in Africa Umbilical cord blood stem cell transplant may help patients with lung, heart disorders UPA Govt. may table Liberhan report, ATR in Parliament today US thanks India for extending hospitality to Dalai Lama New drug target may help treat chronic rhinosinusitis with polyps

Related Latest

NASA's Spitzer telescope observes youngest brown dwarf ever observed Zac Efron admits to stealing movie costumes Kiwi mum says she plays Bach to help cannabis plants grow! Courteney Cox to resume Cougar Town production Fuel vapour exposure increases road rage Exercise 'can cut stroke risk in men' Pak back to singing 'jaded' UN resolutions-for-K-settlement tune Jordan dumps lover Alex Reid Tottenham's Defoe sharpens skills by watching footie greats on YouTube White House keeps suspense alive on Manmohan Singh's banquet details

• NASA's Spitzer telescope observes youngest brown dwarf ever observed
• Zac Efron admits to stealing movie costumes
• Kiwi mum says she plays Bach to help cannabis plants grow!
• Courteney Cox to resume Cougar Town production
• Fuel vapour exposure increases road rage

• भारतीय क्रिकेट की मजबूत दीवार
• कंगारूओं के आगे ढेर, चीतों से कैसे मुकाबला करेंगें शेर
• Reducing greenhouse gases may not be enough to slow global warming
• बीकानेर महापौर चुनावः एक विश्लेषण
• Deepawali: The Festival Of Lights